China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
1.410
-0.020 (-1.40%)
Dec 5, 2025, 4:00 PM EST - Market closed
China SXT Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 1.74 | 1.93 | 1.97 | 2.6 | 4.78 | Upgrade
|
| Revenue Growth (YoY) | -9.73% | -2.19% | -24.23% | -45.53% | -7.45% | Upgrade
|
| Cost of Revenue | 1.37 | 1.37 | 1.55 | 1.35 | 1.94 | Upgrade
|
| Gross Profit | 0.37 | 0.55 | 0.43 | 1.25 | 2.84 | Upgrade
|
| Selling, General & Admin | 3.05 | 2.65 | 5.68 | 6.44 | 5.04 | Upgrade
|
| Operating Expenses | 3.05 | 2.65 | 5.68 | 6.44 | 5.04 | Upgrade
|
| Operating Income | -2.68 | -2.09 | -5.26 | -5.19 | -2.2 | Upgrade
|
| Interest Expense | -0.84 | -0.55 | -0.48 | -0.04 | -1.12 | Upgrade
|
| Interest & Investment Income | 0.19 | 0.01 | - | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | -0.04 | 0.15 | -0.18 | 0.36 | Upgrade
|
| EBT Excluding Unusual Items | -3.3 | -2.68 | -5.59 | -5.41 | -2.94 | Upgrade
|
| Asset Writedown | - | -0.42 | -0.35 | - | - | Upgrade
|
| Pretax Income | -3.3 | -3.1 | -5.93 | -5.41 | -2.94 | Upgrade
|
| Income Tax Expense | - | - | - | 0.33 | -0.19 | Upgrade
|
| Net Income | -3.3 | -3.1 | -5.93 | -5.74 | -2.75 | Upgrade
|
| Net Income to Common | -3.3 | -3.1 | -5.93 | -5.74 | -2.75 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 0 | 0 | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 0 | 0 | - | - | Upgrade
|
| Shares Change (YoY) | 1212.67% | 224.91% | - | - | - | Upgrade
|
| EPS (Basic) | -2.32 | -28.58 | -177.84 | - | - | Upgrade
|
| EPS (Diluted) | -2.32 | -28.58 | -177.84 | - | - | Upgrade
|
| Free Cash Flow | -2.35 | -1.94 | -0.15 | 0.21 | -1.41 | Upgrade
|
| Free Cash Flow Per Share | -1.65 | -17.85 | -4.54 | - | - | Upgrade
|
| Gross Margin | 21.11% | 28.73% | 21.62% | 48.10% | 59.44% | Upgrade
|
| Operating Margin | -153.97% | -108.49% | -266.68% | -199.43% | -45.99% | Upgrade
|
| Profit Margin | -189.77% | -160.67% | -301.00% | -220.43% | -57.52% | Upgrade
|
| Free Cash Flow Margin | -134.83% | -100.34% | -7.68% | 7.91% | -29.50% | Upgrade
|
| EBITDA | -2.6 | -1.89 | -5.01 | -4.87 | -1.85 | Upgrade
|
| EBITDA Margin | -149.24% | -97.95% | -253.99% | -187.13% | -38.76% | Upgrade
|
| D&A For EBITDA | 0.08 | 0.2 | 0.25 | 0.32 | 0.35 | Upgrade
|
| EBIT | -2.68 | -2.09 | -5.26 | -5.19 | -2.2 | Upgrade
|
| EBIT Margin | -153.97% | -108.49% | -266.68% | -199.43% | -45.99% | Upgrade
|
| Revenue as Reported | 1.74 | 1.93 | 1.97 | 2.6 | 4.78 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.